Century Therapeutics
IPSC

$1.46

1.39%

Market Cap: $124M

About: Century Therapeutics Inc is a biotechnology company specializes in leveraging adult stem cells to develop advanced cell therapy products targeting cancer, autoimmune, and inflammatory diseases. Their innovative approach involves a genetically engineered allogeneic cell therapy platform comprising induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and cutting-edge manufacturing capabilities. This comprehensive platform aims to overcome the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and minimizing development and supply risks.

Employees: 165

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,686 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

1,700% more call options, than puts

Call options by funds: $18K | Put options by funds: $1K

121% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 14

9.15% more ownership

Funds ownership: 35.98% [Q1] → 45.13% (+9.15%) [Q2]

0% less capital invested

Capital invested by funds: $97.5M [Q1] → $97.2M (-$230K) [Q2]

8% less funds holding

Funds holding: 66 [Q1] → 61 (-5) [Q2]

42% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 12

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$9

516%

upside

Avg. target

$10.50

619%

upside

High target

$12

722%

upside

2 analyst ratings

2 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Mitchell Kapoor 49% 1-year accuracy 58 / 119 met price target	516%upside $9	Buy Maintained	15 Aug 2024
Piper Sandler Edward Tenthoff 31% 1-year accuracy 11 / 36 met price target	722%upside $12	Overweight Maintained	17 Jun 2024

See Analyst Rankings

Financial journalist opinion

Zacks Investment Research

Century Therapeutics, Inc. (IPSC) Reports Q2 Loss, Tops Revenue Estimates

Century Therapeutics, Inc. (IPSC) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to loss of $0.56 per share a year ago.

Century Therapeutics, Inc. (IPSC) Reports Q2 Loss, Tops Revenue Estimates

Century Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates

– Initiation of Phase 1 CALiPSO-1 Trial of CNTY-101 in Systemic Lupus Erythematosus, marking strategic expansion into autoimmune disease; protocol amended to include additional cohort of Lupus Nephritis patients –

Century Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates

Zacks Investment Research

Century Therapeutics (IPSC) Moves to Buy: Rationale Behind the Upgrade

Century Therapeutics (IPSC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Century Therapeutics (IPSC) Moves to Buy: Rationale Behind the Upgrade

Century Therapeutics: Cell Therapy Biotech With Expanded Potential Of CNTY-101

Positive poster presentation results were released at ASCO 2024 from the phase 1 ELiPSE-1 study, which used CNTY-101 for the treatment of patients with relapsed/refractory CD19-positive non-Hodgkin lymphoma patients. The global non-Hodgkin Lymphoma market is expected to surge to $11 billion by 2029. Initiation of phase 1 CALiPSO-1 study, using CNTY-101 for patients with systemic lupus erythematosus, is expected in the 1st half of 2024; Data from this study is to be released 2nd half of 2024.

Century Therapeutics: Cell Therapy Biotech With Expanded Potential Of CNTY-101

Century Therapeutics Presents Interim Results from Phase 1 ELiPSE-1 Study at ASCO 2024 Annual Meeting

In ongoing dose escalation, CNTY-101 has demonstrated a manageable safety profile with no observed DLTs or GvHD and with majority of patients treated in outpatient setting

Century Therapeutics Presents Interim Results from Phase 1 ELiPSE-1 Study at ASCO 2024 Annual Meeting

Zacks Investment Research

Century Therapeutics, Inc. (IPSC) Reports Q1 Loss, Tops Revenue Estimates

Century Therapeutics, Inc. (IPSC) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to loss of $0.53 per share a year ago.

Century Therapeutics, Inc. (IPSC) Reports Q1 Loss, Tops Revenue Estimates

Century Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

- Announced plans to pursue additional autoimmune disease regulatory filings for its iPSC derived NK cell therapy, CNTY-101, beyond systemic lupus erythematosus (SLE)

Century Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

Century Therapeutics to Present at Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

PHILADELPHIA, April 23, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that members of the management team will participate in a virtual fireside chat and panel at Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit, details of the presentations are as follows:

Century Therapeutics to Present at Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics

Century is pursuing additional autoimmune disease regulatory filings for its iPSC derived iNK cell therapy, CNTY-101, beyond CALiPSO-1 trial in SLE, based on the potential of its differentiated profile

Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics

Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting

PHILADELPHIA, April 08, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that preclinical data from the Company's iPSC-derived cell therapy platform was presented at the AACR Annual Meeting 2024. The posters highlight the Company's end-to-end capabilities in iPSC reprogramming and differentiation, gene editing, synthetic biology, protein engineering and computational biology.

Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting

See News Rankings